CIK 0001613780 · Non-accelerated filer<br>Smaller reporting company
DBV Technologies S.A.
Sign in to watch- Ticker
- DBVTF
- Exchange
- Nasdaq, OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- France
- Entity type
- operating
- Phone
- 330155427878
- Business address
- 107 AVENUE DE LA REPUBLIQUE, CHATILLON, France
Securities
- DBVT American Depositary Shares Nasdaq
- DBVTF Common stock OTC
- 8-K Event Shareholder rights changed · Regulation FD disclosure
- 4 Open-market sale Chief Medical Officer sold 1,042 shares at an average $1.37 ($1,425)
- F-6 POS Other F-6 POS
- 8-K Event Shareholder rights changed · Regulation FD disclosure
- 8-K Event Bylaws or fiscal year change · Shareholder vote results
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- ARS Other Annual Report to Security Holders
- DEF 14A Proxy Proxy Statement
- PRE 14A Proxy Proxy Statement (Preliminary)
- 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 17,094 shares at $0.83 ($14,188)
- 8-K Event Regulation FD disclosure
- 10-K Report Annual Report
- 8-K Event Results of operations
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market buy Director bought 1,825 shares at $0.89 ($1,624)
- 8-K Event Delisting notice
- 4 Open-market sale Chief Medical Officer sold 2,245 shares at $1.74 ($3,906)
- 4 Grant or award Chief Financial Officer acquired 19,000 shares (grant or award)
Page 7 of 29 · 577 filings